Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | Repurposing monoclonal antibodies in the face of the COVID-19 pandemic

Christian Chabannon • 1 Sep 2020
EBMT 2020
General Antibodies Tocilizumab

Christian Chabannon, MD, PhD, Aix Marseille University (AMU) School of Medicine, Marseille, France, discusses the repurposing of monoclonal antibodies and other immunotherapies during the COVID-19, with the aim of modulating the hyper-immune response associated with the disease. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Disclosures

Sanofi SA, Kite / Gilead, Novartis, Celgene / BMS, Janssen, Bellicum Pharmaceuticals, Terumo BCT: speakers bureau & advisory boards

More from Christian Chabannon

The role and importance of accreditation in the changing landscape of cellular therapies in Europe
1:13
The role and importance of accreditation in the changing landscape of cellular therapies in Europe
Christian Chabannon • 25 Mar 2026
Ongoing efforts to improve training and education in transplantation and cellular therapy
1:45
Ongoing efforts to improve training and education in transplantation and cellular therapy
Christian Chabannon • 25 Mar 2026
Aiming to optimize lymphodepletion strategies to enhance CAR-T efficacy
1:07
Aiming to optimize lymphodepletion strategies to enhance CAR-T efficacy
Christian Chabannon • 7 Feb 2025
Improving access to CAR-T in Europe: training HCPs and developing the CAR-T passport
1:19
Improving access to CAR-T in Europe: training HCPs and developing the CAR-T passport
Christian Chabannon • 7 Feb 2025

Related Videos

The ethical challenges of AI in hematology: patient communication, trust and regulation
3:12
The ethical challenges of AI in hematology: patient communication, trust and regulation
Adrián Mosquera Orgueira • 24 Sep 2026
The future of AI in hematology: personalized medicine, opportunities and risks
2:30
The future of AI in hematology: personalized medicine, opportunities and risks
Adrián Mosquera Orgueira • 24 Sep 2026
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
5:18
The multi-system impacts of CHIP and its link to subspecialties within internal medicine
Shyam Patel • 13 Oct 2026
The scientific and clinical implications of therapy-related CHIP in oncology
2:43
The scientific and clinical implications of therapy-related CHIP in oncology
Shyam Patel • 13 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals